In a large retrospective study, those taking a glucagon-like peptide 1 (GLP-1) receptor agonist drug were 36% less likely to develop colorectal cancer than those taking aspirin. Although the benefit ...
1Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California. 2Cancer Institute, Stanford University School of Medicine, Stanford, ...
1Division of Surgical Oncology, Dewitt Daughtry Department of Surgery, University of Miami, Miami, Florida. 2Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami ...
Abstract. At its core, cancer is a disease of uncontrolled cell proliferation mediated by perturbed molecular pathways that have been elucidated over the past few decades. Biochemical and genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results